Stock AnalizGLAUKOS Corp GKOS
Medical/Dental Instruments · IPO 2015 · data as of November 13, 2026
GLAUKOS Corp (GKOS) is a healthcare company listed in the US with a market value of about $14.5B. In the twelve months to September 30, 2026 it had revenue of $690M and net income of -$170M, a net margin of -24.6%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 403.8, 5-year revenue growth of 18% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $690M | $507M | $383M | $315M | $283M | $294M | $225M | $237M | $181M | $159M | $114M |
| Net income | -$170M | -$188M | -$146M | -$135M | -$99M | -$50M | -$120M | $15M | -$13M | -$92000 | $5M |
| Free cash flow | $36M | -$22M | -$68M | -$78M | -$63M | -$23M | -$30M | -$5M | $9M | $20M | $6M |
| EPS (diluted) | $-2.95 | $-3.28 | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.37 | $-0.37 | $0.00 | $0.12 |
| Net margin | -24.6% | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | -53.5% | 6.5% | -7.1% | -0.1% | 4.0% |
| ROIC | — | -28.0% | -12.0% | -20.6% | -11.6% | -4.2% | -16.3% | -5.8% | -5.9% | -1.3% | 3.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $242.46, 1% below the current price; targets range from $225.00 to $270.00; the consensus rating is “Strong buy”; expected EPS is $0.64 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is GLAUKOS stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does GLAUKOS pay a dividend?
Not currently.
Is GLAUKOS a good stock to buy?
We do not give buy or sell advice. GLAUKOS scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.